Akebia Therapeutics, Inc. (AKBA)

Akebia Therapeutics Statistics

Total Valuation

AKBA has a market cap or net worth of $621.73 million. The enterprise value is $758.59 million.

Market Cap	621.73M
Enterprise Value	758.59M

Important Dates

The next estimated earnings date is Thursday, May 8, 2025, before market open.

Earnings Date	May 8, 2025
Ex-Dividend Date	n/a

Share Statistics

AKBA has 261.23 million shares outstanding. The number of shares has increased by 12.53% in one year.

Current Share Class	261.23M
Shares Outstanding	261.23M
Shares Change (YoY)	+12.53%
Shares Change (QoQ)	+3.97%
Owned by Insiders (%)	2.20%
Owned by Institutions (%)	26.03%
Float	255.49M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	3.13
Forward PS	3.16
PB Ratio	-12.64
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	4.74
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.41

Current Ratio	1.41
Quick Ratio	1.07
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-2.54

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-12.49%
Return on Invested Capital (ROIC)	-22.81%
Return on Capital Employed (ROCE)	-33.06%
Revenue Per Employee	$884,972
Profits Per Employee	-$383,481
Employee Count	181
Asset Turnover	0.69
Inventory Turnover	1.64

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +73.72% in the last 52 weeks. The beta is 0.86, so AKBA's price volatility has been lower than the market average.

Beta (5Y)	0.86
52-Week Price Change	+73.72%
50-Day Moving Average	1.96
200-Day Moving Average	1.74
Relative Strength Index (RSI)	67.23
Average Volume (20 Days)	4,149,904

Short Selling Information

The latest short interest is 17.36 million, so 6.64% of the outstanding shares have been sold short.

Short Interest	17.36M
Short Previous Month	16.57M
Short % of Shares Out	6.64%
Short % of Float	6.79%
Short Ratio (days to cover)	3.07

Income Statement

In the last 12 months, AKBA had revenue of $160.18 million and -$69.41 million in losses. Loss per share was -$0.33.

Revenue	160.18M
Gross Profit	134.03M
Operating Income	-46.21M
Pretax Income	-40.44M
Net Income	-69.41M
EBITDA	-8.70M
EBIT	-46.21M
Loss Per Share	-$0.33

Balance Sheet

The company has $51.87 million in cash and $188.73 million in debt, giving a net cash position of -$136.86 million or -$0.52 per share.

Cash & Cash Equivalents	51.87M
Total Debt	188.73M
Net Cash	-136.86M
Net Cash Per Share	-$0.52
Equity (Book Value)	-49.19M
Book Value Per Share	-0.22
Working Capital	32.92M

Cash Flow

In the last 12 months, operating cash flow was -$40.66 million and capital expenditures -$33,000, giving a free cash flow of -$40.69 million.

Operating Cash Flow	-40.66M
Capital Expenditures	-33,000
Free Cash Flow	-40.69M
FCF Per Share	-$0.16

Margins

Gross margin is 83.68%, with operating and profit margins of -28.85% and -43.33%.

Gross Margin	83.68%
Operating Margin	-28.85%
Pretax Margin	-43.33%
Profit Margin	-43.33%
EBITDA Margin	-5.43%
EBIT Margin	-28.85%
FCF Margin	n/a

Dividends & Yields

AKBA does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-12.53%
Shareholder Yield	-12.53%
Earnings Yield	-11.16%
FCF Yield	-6.54%

Analyst Forecast

The average price target for AKBA is $6.50, which is 173.11% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$6.50
Price Target Difference	173.11%
Analyst Consensus	Strong Buy
Analyst Count	3
Revenue Growth Forecast (5Y)	34.55%
EPS Growth Forecast (5Y)	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

AKBA has an Altman Z-Score of -9.75 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-9.75
Piotroski F-Score	4